Federal News Update: FDA RTF decision, FY26 funding secured, and FDA Modernization Act 3.0
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Federal News Update: FDA Releases Guidance on Modernizing Statistical Methods in Clinical Trials
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
AMRC publishes 2026 positioning paper
At the beginning of 2025, AMRC set out to champion the multisite clinical research corporation (MCRC) model and to ensure that Sponsors, CROs, policymakers, and the wider industry understood its advantages.
Federal News Update: White House Seeks Input on Science and Research and President Trump Announces Genesis Mission
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Federal News Update: Senate votes to reopen the federal government, FDA Announces National Priority Voucher Awards and Trump Administration Lowers Cost of GLP-1s
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Federal News Update: Federal Shutdown Impacts NIH Operations as FDA Targets Trial Reporting Gaps
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
AMRC welcomes three new members
The Association of Multisite Research Corporations (AMRC) today announced the addition of three new members,Rovia Clinical Research, K2 Medical Research, and Eximia, further expanding its representation of leading multisite research organizations across the United States and internationally.
Clinical Trials Sector Braces for Wave of M&A
When Headlands Research was acquired by THL Partners earlier this year, the deal sent a clear signal: consolidation in the clinical trials sector is accelerating. Investors are taking a hard look at the potential of site networks and multisite clinical research corporations (MCRCs) to deliver the scale, quality, and efficiency demanded by sponsors, CROs, and patients.
From headwinds to tailwinds: what can we expect for the rest of 2025 in clinical trials?
There’s an ancient Chinese expression that says, “may you live in interesting times.” For the clinical trial industry, the word “interesting” doesn’t even begin to cover the roller-coaster ride of regulatory changes, disappearing grants, and general uncertainty it’s endured over the past six to twelve months.
Federal News Update: Major CDC Shakeup, FY26 Funding, and New Trial Access Bill
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
